Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01716247 · ClinicalTrials.gov registry record · NA
Comparison of Contrast Enhanced Mammography to Breast MRI in Screening Patients at Increased Risk for Breast Cancer
A NA study of Women at Increased Risk for Developing Breast Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 1
- Study location
NCT01716247: Completed NA study of Women at Increased Risk for Developing Breast Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01716247 is a NA study of Women at Increased Risk for Developing Breast Carcinoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 1,000 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01716247, a NA study of Women at Increased Risk for Developing Breast Carcinoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if Contrast Enhanced Spectral Mammography (CESM) will be able to detect smaller/earlier breast cancers as well as breast MRI can.
Primary Outcome
CESM to that of breast MRI in a population of women who are being screened because they are at increased risk for developing breast cancer. For this purpose a positive CESM test will be defined as a score of 4 or 5. We will use the existing MRI BIRADS system to score CESM images based on the characteristics of individual lesions and increased enhancement compared to the background. A positive MRI test will be defined by a BIRADs score of 4 or 5.
Conditions Studied
Interventions
- OTHER Mammography (CESM) and MRI
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2012-10 |
| Est. Completion | 2018-06 |
| Phase | NA |
What the finished NCT01716247 record still lists
NCT01716247 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower).
The record links to 1 condition, with Women at Increased Risk for Developing Breast Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Mammography (CESM) and MRI is the first listed.
NCT01716247 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01716247 about?
NCT01716247 is a clinical study titled "Comparison of Contrast Enhanced Mammography to Breast MRI in Screening Patients at Increased Risk for Breast Cancer". The purpose of this study is to determine if Contrast Enhanced Spectral Mammography (CESM) will be able to detect smaller/earlier breast cancers as well as breast MRI can.
What is the current status of trial NCT01716247?
This trial is currently completed. It is a NA study. The enrollment target is 1,000 participants. The study started on 2012-10. Estimated completion is 2018-06.
What conditions does trial NCT01716247 study?
This clinical trial studies the following conditions: Women at Increased Risk for Developing Breast Carcinoma.
What interventions are being tested in trial NCT01716247?
The interventions under investigation include: Mammography (CESM) and MRI (OTHER).
Who is sponsoring clinical trial NCT01716247?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01716247 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01716247's enrollment target sits among peer trials
1,000 107th of 2000 higher than 1,880 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia